CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Josh Cohen

Co-Chief Executive Officer, Co-Founder and Director, Amylyx Pharmaceuticals, Inc.

Search every verified Josh Cohen interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Josh Cohen, co-founder and co-CEO of Amylyx Pharmaceuticals, has discussed the company's work on neurodegenerative diseases, including the development and regulatory path of AMX0035, known commercially as Relyvrio in the US and Albrioza in Canada. In a June 2024 podcast, he described the CENTAUR trial as the first study in ALS to show both slowed disease progression and a survival benefit in a single trial, which led to FDA approval. He also noted that the company was still collecting survival data and examining differences between the CENTAUR and later PHOENIX trials, while reflecting on the broader state of neurodegenerative disease research, comparing it to where oncology was 20 to 25 years ago. Cohen has also spoken about the urgency of addressing brain health and the importance of multi-stakeholder collaboration. At a September 2023 event tied to the UN General Assembly, he described a "golden era of brain science" and emphasized the need for policy engagement, citing the launch of the EU ALS Coalition as an example. He has highlighted the rapid progression of ALS—noting that patients can go from fully functional to fully paralyzed within two years—and stressed the obligation of pharmaceutical companies to support care and access beyond drug development. In earlier remarks, he recounted the decision to build Amylyx independently rather than sell or partner with a larger company, citing a responsibility to the ALS community.

Recent appearances

  • The Road Ahead for Former ALS Hopeful Relyvrio ft. Amylyx's Joshua Cohen and Justin Klee

    June 19, 2024 · 📺 Xtalks

    In this episode, Ayesha spoke with Joshua Cohen and Justin Klee, co-CEOs and co-founders of Amylyx Pharmaceuticals, a company developing therapeutics for neurodegenerative diseases like amyotrophic lateral sclerosis (ALS). Josh and Justin co-founded Amylyx Pharmaceuticals in 2013. Josh co-invented the oral, fixed-dose combination AMX0035 (known commercially as Albrioza in Canada and Relyvrio in the US), which is being explored for the potential treatment of neurodegenerative diseases. With a background in biomedical engineering, Josh is passionate about improving outcomes where there is a sig…

    Watch on YouTube ↗

  • Brain Health & Research at UNGA78 | Justin Klee & Josh Cohen, Amylyx

    November 30, 2023 · 📺 European Brain Council

    As part of the European Brain Council (EBC)’s Global Partnerships in Brain Research activities, EBC, in collaboration with the Baker Institute for Public Policy, the Brain Capital Alliance, and the Brain Health Nexus organised an event last September 2023 at the Science Summit at the 78th United Nations General Assembly (UNGA78). Across the globe, society is facing brain challenges like never before—improving the health and well-being of citizens has become the top priority for many governments and brain health should not be left behind. Brain disorders, neurological and mental alike, are per…

    Watch on YouTube ↗

  • Joshua Cohen and Justin Klee, Amylyx, 2022 Harvey & Bonny Gaffen Advancements in ALS Award Honorees

    May 24, 2022 · 📺 Les Turner ALS Foundation

    Co-Founders and Co-CEOs of Amylyx Pharmaceuticals, Inc., Joshua Cohen and Justin Klee, were our 2022 Harvey & Bonny Gaffen Advancements in ALS Award Honorees.

    Watch on YouTube ↗

  • Carney Conversations: From a Brown dorm room to a potential treatment for neurodegenerative diseases

    May 05, 2021 · 📺 Brown University

    Join the Carney Institute for Brain Science for a conversation with Brown University alumni Josh Cohen and Justin Klee about their journey from a dorm room to the development of a potential treatment for neurodegenerative diseases, such as Alzheimer’s and ALS. Cohen and Klee are the founders of Amylyx, a Cambridge-based pharmaceutical company dedicated to the development of therapeutics for neurodegenerative disorders. This conversation was moderated by Diane Lipscombe, Reliance Dhirubhai Ambani Director of the Carney Institute, and Christopher Moore, associate director of the Carney Instit…

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →